Department of Respiratory Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, Japan.
Department of Emergency Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
BMC Pulm Med. 2018 Feb 7;18(1):28. doi: 10.1186/s12890-018-0597-5.
In the 1980s, randomized-controlled trials showed that high-dose corticosteroid treatment did not improve the mortality of acute respiratory distress syndrome (ARDS). However, while the diagnostic criteria for ARDS have since changed, and supportive therapies have been improved, no randomized-controlled trials have revisited this issue since 1987; thus, the effect of high-dose corticosteroid treatment may be different in this era. We evaluated the effect of high-dose corticosteroid treatment in patients with ARDS using a nationwide administrative database in Japan in a retrospective and observational study.
This study was performed with a large population using the 2012 Japanese nationwide administrative database (diagnostic procedure combination). We evaluated the mortality of ARDS patients receiving or not receiving high-dose corticosteroid treatment within 7 days of hospital admission. We employed propensity score weighting with a Cox proportional hazards model in order to minimize the bias associated with the retrospective collection of data on baseline characteristics and compared the mortality between the high-dose and non-high-dose corticosteroid groups.
Data from 2707 patients were used; 927 patients were treated with high-dose corticosteroid and 1780 patients were treated without high-dose corticosteroid, within 7 days of admission. After adjusting for confounds, mortality rates within 3 months were significantly higher in the high-dose corticosteroid group compared to the non-high-dose corticosteroid group (weighted hazard ratio: 1.59; 95% CI: 1.37-1.84; P < 0.001).
Our results suggest that high-dose corticosteroid treatment does not improve the prognosis of patients with ARDS, even in this era. However, this study has limitations owing to its retrospective and observational design.
20 世纪 80 年代,随机对照试验表明,大剂量皮质类固醇治疗并未改善急性呼吸窘迫综合征(ARDS)的死亡率。然而,尽管 ARDS 的诊断标准自那时以来已经发生了变化,支持性治疗也得到了改善,但自 1987 年以来,尚无随机对照试验重新探讨这一问题;因此,大剂量皮质类固醇治疗的效果在这个时代可能有所不同。我们使用日本全国性行政数据库,在回顾性和观察性研究中评估了 ARDS 患者接受或不接受大剂量皮质类固醇治疗的效果。
本研究使用了大量人群,使用了 2012 年日本全国性行政数据库(诊断程序组合)。我们评估了入院后 7 天内接受或未接受大剂量皮质类固醇治疗的 ARDS 患者的死亡率。我们采用倾向评分加权 Cox 比例风险模型,以最小化与回顾性收集基线特征相关的偏倚,并比较了大剂量和非大剂量皮质类固醇组之间的死亡率。
共使用了 2707 例患者的数据;927 例患者接受了大剂量皮质类固醇治疗,1780 例患者在入院后 7 天内未接受大剂量皮质类固醇治疗。调整混杂因素后,大剂量皮质类固醇组 3 个月内的死亡率明显高于非大剂量皮质类固醇组(加权风险比:1.59;95%CI:1.37-1.84;P<0.001)。
我们的结果表明,即使在这个时代,大剂量皮质类固醇治疗也不能改善 ARDS 患者的预后。然而,由于本研究为回顾性和观察性设计,存在一定的局限性。